We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Monopar Therapeutics Inc | NASDAQ:MNPR | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.0111 | 1.81% | 0.6236 | 0.605 | 0.629 | 0.6502 | 0.605 | 0.6111 | 32,333 | 21:57:35 |
From Jun 2023 to Jun 2024
Fireside Chat Details:Date: June 20, 2023Time: 1:30 pm ETLocation: Virtual Conference
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, visit: www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc. Investor Relations Kim R. Tsuchimoto Chief Financial Officer kimtsu@monopartx.com
Follow Monopar on social media for updates: Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
1 Year Monopar Therapeutics Chart |
1 Month Monopar Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
